Instructions for Authors 2017

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trial number should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. There is no fee for this service. Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Results given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   • The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal's policy.
   • they do not follow the instructions for authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

- The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Wound Healing is Delayed in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (St. Paul, MN; Indianapolis, IN, USA)

Active and Passive Immunization Against Staphylococcus aureus Periprosthetic Osteomyelitis in Rats. N.H. SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA)


A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (California; Pittsburgh, PA; Newark, NJ, USA)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (Copenhagen, Denmark)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (Saitama, Japan)


Induction of TGF-β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (Pittsburgh, PA, USA)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITA, S. INABA (Nara, Japan)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSEN, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (Odense; Copenhagen, Denmark)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLUND (Tromso; Bodø, Norway)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (Jackson, MS, USA)
A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (Spokane, WA; Duarte, CA, USA)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (Basel, Switzerland)


Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATHEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (Los Angeles, CA; Boston, MA, USA; London, UK)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Basel, Switzerland)


High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (Vitis vinifera) in HeLa cells. E.A. MAZZIO, K.A. SOLIMAN (Tallahassee, FL, USA)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (Austin, TX; Cambridge, MA, USA)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (Uppsala; Halmstad, Sweden)


Overexpression of HPV16 E6* Alters β-Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (Loma Linda, CA, USA)
Subscription Order Form 2017

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 37 (2017).
  Annual subscription rates (2017): Institutional, US$ 1898.00 online, US$ 2277.00 online & print; Personal, US$ 897.00 online; US$ 1277.00 online & print; Prices include rapid delivery and insurance.
  2017 online subscriptions include free online access to vol. 24 (2004) - 36 (2016).

☐ Please send me the following previous volumes (1-36) at 50% discount on the above rates:
☐ Please invoice.
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ................................................................................................................................................................
.................................................................................................................................................................................................
Tel: ..........................................................................................................................................................................................
Fax: ....................................................................................................................... e-mail: ..............................................
Signature:............................................................................................................... Date: .............................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2017 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2017 on a basis of priority and availability. Effective from January to December 2017).

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2017

☐ I am one of the authors of the article published in Anticancer Research Vol........., pp. ............, year ..............
☐ Please enter my personal subscription to Anticancer Research 2017 (Volume 37) at the special Author’s rate of US$ 465.00 (print or online).
☐ Please send me previous Volume No(s) ................. at US$ 224.00 (print) per volume.
☐ Please send me an invoice.

Prices include rapid delivery and insurance.

Name and address: ................................................................................................................................................................
.................................................................................................................................................................................................
Tel-Fax: ..........................................................................................................................................................................................
e-mail: ...................................................................................................................................................................................
Date and signature: ................................................................................................................................................................
Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer. R. CELIK, R. SEMRAU, C. BAUES, M. TROMMER-NESTLER, W. BAUS, S. MARNITZ (Cologne, Germany) ........................................................................................................................................................................ 5285

Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence. M. ISHITOBI, R. FUKUI, Y. HASHIMOTO, N. KITAKA, T. NAKAYAMA, Y. TAMAKI (Osaka, Japan) .......................... 5293


Study on the Validity of Pancreaticoduodenectomy in the Elderly. Y. FUTAGAWA, M. KANEHIRA, K. FURUKAWA, H. KITAMURA, S. YOSHIDA, T. USUBA, T. MISAWA, Y. ISHIDA, T. OKAMOTO, K. YANAGA (Tokyo, Japan) ....................................................................................................................................................... 5309

Errata..................................................................................................................................................................................................................... 5317

First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen). G. SCHINZARI, E. ROSSI, G. MAMBELLA, A. STRIPPOLI, R. CANGIANO, M. MUTIGNANI, M. BASSO, A. CASSANO, C. BARONE (Rome; Potenza; Caserta; Milan, Italy) .................................................. 5193


Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposommes. Y. BI, Y. ZHOU, M. WANG, L. LI, R.J. LEE, J. XIE, L. TENG (Changchun; Zhuhai, PR China; Columbus, OH, USA) ............. 5207


Anti-proliferative, Cytotoxic and NF-κB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia. M.M. BOUHENNA, B. ORLIKOVA, O. TALHI, B. SCHRAM, D.C.G.A. PINTO, N. TAIBI, K. BACHARI, M. DIEDERICHER, A.M.S. SILVA, N. MAMERI (Alger; Tipaza, Algeria; Seoul, Republic of Korea; Luxembourg City, Luxembourg; Aveiro, Portugal) ............................................................ 5225

Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin. A. MAEDA, H. ANDO, T. URA, K. MURO, M. AOKI, K. SAITO, E. KONDO, S. TAKAHASHI, Y. ITO, Y. MIZUNO, A. FUJIMURA (Nagoya; Tochigi; Niigata, Japan) ............................................................................ 5235


The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity. N. YAMASHITA, E. TOKUNAGA, H. YAMAMOTO, C. SHIMIZU, K. TAKETANI, Y. INOUE, H. SAEKI, E. OKI, Y. MAEHARA (Fukuoka; Tokyo, Japan) ............................................................................................................ 5249


Are Multiple Tumors of the Parotid Gland Uncommon or Underestimated? A.M. FRANZEN, A. COORDES, C.K. FRANZEN, T. GUENZEL (Newruppin; Berlin; Leer, Germany) .................................................................................................................. 5263

Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreatectoduodenectomy for Pancreatic Adenocarcinoma in Patients Undergoing Salvage Pancreatectomy. A. ANDREOU, F. KLEIN, R.B. SCHMUCK, D. LEE, M. SINN, T. DENECKE, J. PRATSCHKE, M. BAHRA (Berlin, Germany) .................................................................................................................. 5269

Surgical Strategy for T1 Duodenal or Ampullary Carcinoma According to the Depth of Tumor Invasion. A. KOHGA, Y. YAMAMOTO, S. SANO, T. SUGIURA, Y. OKAMURA, T. ITO, R. ASHIDA, H. ISHIWATARI, H. MATSUBAYASHI, K. SASAKI, K. UESAKA (Shizuoka, Japan) ................................................................................. 5277

Inconsistent Reporting Between Meta-analysis Protocol and Publication – A Cross-Sectional Study. ALBERTO F. DELGADO, ANNA F. DELGADO (Uppsala; Stockholm, Sweden)............................ 5101

Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy. M.-B. CHEN, D.A. LABER (Kunshan, PR China; Tampa, FL, USA) .................. 5109

Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up. F. AMPIL, S. ELLIKA, A. NANDA, M. VORA (Shreveport, LA, USA)................................. 5113

Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel. J. VON HARDENBERG, M. SCHWARTZ, T. WERNER, S. FUXIUS, M. MÜLLER, T. FRANGENHEIM, C. BOLENZ, C. WEISS, E. HEINRICH (Mannheim; Herzberg am Harz; Heidelberg; Ludwigshafen; Bruchsal; Goettingen, Germany) ................................................................. 5117


Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC. R. HAMAGUCHI, T. OKAMOTO, M. SATO, M. HASEGAWA, H. WADA (Kyoto, Japan; Cleveland, OH, USA) .................. 5141

Evaluation of Factors Affecting Metastasis for Renal Cell Carcinoma Based on Current Guidelines in Japan. Y. KADONO, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. NARIMOTO, K. ISUMI, H. IKEDA, H. YAEGASHI, T. MIYAGI, T. NAKASHIMA, C. SETO, A. MIZokAMI (Kanazawa; Toyama, Japan) .... 5147


Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. T. SHINTANI, Y. MATSUO, Y. IIZUKA, T. MITSUYOSHI, T. MIZOWAKI, M. HIRAOKA (Kyoto, Japan) .......................................................................................................................................................... 5161

A Scoring System to Predict the Development of Bone Metastasis After Radical Resection of Colorectal Cancer. A. LI, L. KÅSMANN, D. RADES, C. FU (Shanghai, PR China; Lübeck, Germany) .................. 5169

Comparison of Postoperative Outcomes Between Laparoscopic and Open Surgery for Colorectal Cancer. K. NEKI, K. ETO, M. LOSUGE, M. OHKUMA, R. NOAKI, R. HASHIZUME, S. SASAKI, Y. SHIRAI, K. YANAGA (Tokyo, Japan) ................................................................. 5173

Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions. B. WOJTCZAK, B. PULA, A. GOMULKIEWICZ, M. OLBRONSKII, M. PODHORSKA-OKOLOW, P. DOMOSLAWSKI, M. BOLANOWSKI, J. DAROSZEWSKI, P. DZIEGIEL (Wroclaw, Poland) ........................................................................................................ 5179

Contents continued on the preceding page
Hedgehog Stimulation Suppresses Clonogenicity and Activates NOTCH Signalling in T-lymphoblastic Leukaemia Jurkat Cells. Y. OKUHASHI, M. ITOH, S. TOHDA (Tokyo, Japan) ................................................................. 5005


Clinical Studies


Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer. X. WU, P. REINIKAINEN, M. KAPANEN, T. VIERIKKO, P. RYYMIN, P.-L. KELLOKUMPU-LEHTINEN (Tampere, Finland) ................................................................................................................................. 5033


Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma. A. KUMABE, S. ZENDA, A. MOTEGI, M. ONOZAWA, N. NAKAMURA, T. KOJIMA, H. DAIKO, N. SHIGEMATSU, T. AKIMOTO (Tokyo; Kashiwa, Japan) ................................................................................................................................. 5045


Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings. T. FUJII, K. YANAI, S. TOKUDA, Y. NAKAZAWA, S. KUROZUMI, S. OBAYASHI, R. YAJIMA, T. HIRAKATA, H. KUWANO (Gunma, Japan) ................................................................................................................................. 5057

Inflammatory Breast Cancer Outcomes in a Contemporary Series. E. PAN, L. TUNG, O. RAGAB, E. MOROCCO, J. WECSLER, R. SPOSTO, A. RAGHAVENDRA, E. CHUNG, J.E. LANG (Los Angeles, CA, USA) ................................................................................................................................. 5061

Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy. C. EICHLER, S. ABRAR, J. PUPPE, M. ARNDT, R. OHLINGER, M. HAHN, M. WARM (Cologne; Greifswald; Tuebingen, Germany) ................................................................................................................................. 5065

Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer. M. WAKAHARA, T. SAKABE, Y. KUBOUCHI, K. HOOSAYA, Y. HIROOKA, Y. YURUGI, K. NOSAKA, T. SHIOMI, H. NAKAMURA, Y. UMEKITA (Tottori, Japan) ................................................................................................................................. 5071


Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. H.M. KORASHY, Z.H. MAAYAH, F.E. AL ANAZI, A.M. ALSAAD, I.O. ALANAZI, O.M. BELALI, F.O. AL-ATAWI, A. ALSHAMSAN (Riyadh, Kingdom of Saudi Arabia) .................................................................................................................................................................. 4899

Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-κB Activation in Osteosarcoma U2OS Cells. P.-J. PAN, J.-J. TSAI, Y.-C. LIU (Yilan; Taipei; Taichung, Taiwan, ROC) .......... 4911

Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells. F.-T. HSU, C.-C. SUN, C.-H. WU, Y.-J. LEE, C.-H. CHIANG, W.-S. WANG (Taipei; Yilan; New Taipei City; Kaohsiung, Taiwan, ROC) ....... 4919

An Adaptation System to Avoid Apoptosis via Autophagy Under Hypoxic Conditions in Pancreatic Cancer Cells. S. OWADA, K. ITO, H. ENDO, Y. SHIDA, C. OKADA, T. NEZU, M. TATEMICHI (Isehara, Japan) ........... 4927


GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells. J.H. LEE, Y.M. YOON, S.H. LEE (Birmingham, AL, USA; Seoul; Cheonan, Republic of Korea) ........ 4943

The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status. J.K. BAR, A. LIS-NAWARA, P. GRELEWSKI, L. NOGA, Z. GRZEBIENIAK, M. JELEŃ (Wroclaw, Poland) .................................................................................................. 4953

The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients. K. ORYWAL, W. JELSKI, T. WEREL, M. SZMITKOWSKI (Bialystok, Poland) .............................................................................................................................. 4961

The Impact of Environmental Light Intensity on Experimental Tumor Growth. M.A. SUCKOW, W.R. WOLTER, G.E. DUFFIELD (St. Paul, MN; Notre Dame, IN, USA) ............................................................................. 4967


Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer. T. SHIMURA, M. SHIBATA, K. GONDA, Y. KOFUNATO, R. OKADA, T. ISHIGAME, T. KIMURA, A. KENJO, K. KONO, S. MARUBASHI (Fukushima, Japan) ...................................................................................................................... 4979

Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells. H. ONISHI, K. NAKAMURA, S. NAGAI, K. YANAI, A. YAMASAKI, M. KAWAMOTO, A. IMAIZUMI, T. MORISAKI (Fukuoka; Tokyo, Japan) .......................................................................................... 4987

Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning – A Phantom Study. J. WIKSTROM, U. ISACSSON, B. JOHANSSON, B. LENNERNÄS (Uppsala; Örebro, Sweden) ................. 4993

Role of Caspase-9 Gene Ex5+32 G>A (rs1052576) Variant in Susceptibility to Primary Brain Tumors. S. OZDOGAN, A. KAFADAR, S.G. YILMAZ, O. TIMIRCI-KAHRAMAN, U. GORMUS, T. ISBIR (Istanbul, Turkey) ............................................................. 4997

Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. S. KASE, K. ISHIJIMA, T. URAKI, Y. SUIMON, Y. SUZUKI, M. KASE, S. ISHIDA (Sapporo, Japan) .............................................................................................................. 5001

Contents continued on the preceding page
Phosphoproteomic Analysis Identifies Signaling Pathways Regulated by Curcumin in Human Colon Cancer Cells. T. SATO, Y. HIGUCHI, Y. SHIBAGAKI, S. HATTORI (Tokyo; Nagoya, Japan) ....................... 4789

Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2. A. KUBAN-JANKOWSKA, K.K. SAHU, M. GORSKA-PONIKOWSKA, J.A. TUSZYNSKI, M. WOZNIAK (Gdansk, Poland; Edmonton, Canada) ........................................................................................................... 4799

Effective Metabolic Targeting of Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models with Recombinant Methioninase. K. IGARASHI, K. KAWAGUCHI, T. KIYUNA, K. MIYAKE, T. MURAKAMI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, H. TSUCHIYA, R.M. HOFFMAN (San Diego, CA, USA; Kanazawa, Japan) .......................................................................................................................... 4807

Probing the Molecular Mechanisms Governing the Oncolytic Activity of Paeonia suffruticosa on Triple-negative Breast Cancer Cells In Vitro. D. KIM, D. RADIN, D. LEONARDI (St. Louis, MO; New York, NY; Hackensack, NJ, USA) ............................................................................................................................................ 4813

Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia. M. VORA, L.A. ALATTIA, J. ANSARI, M. ONG, J. COTELINGAM, D. COPPOLA, R. SHACKELFORD (Shreveport, LA; Tampa, FL, USA) .................................................................................................................................................................. 4821

Communicate or Die – A Model for HPV+ and HPV– CSCs and Their Interactions with SDF-1α. F. JUNGBAUER, C. ADERHOLD, R. BIRK, K. HOERMANN, B. KRAMER, B. KUHLIN, C. THORN, C. UMBREIT, A. LAMMERT (Mannheim; Marburg; Jena, Germany) .................................................................................. 4827

Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells. S. UEHARA, K. SAITO, H. ASAMI, Y. OHTA (Kanagawa, Japan) ...................................................................................................................................................................................................... 4837

Increased CXCL8 Expression Is Negatively Correlated with the Overall Survival of Patients with ER-Negative Breast Cancer. Q. FANG, X. WANG, G. LUO, M. YU, X. ZHANG, N. XU (Changzhou, PR China; Lund, Sweden) .......................................................................................................................................................... 4845

Transforming Growth Factor-β, Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma. D. PACHNIA, B. DROP, A. DWORZAŃSKA, E. KLISZCZEWSKA, M. POLZ-DACEWICZ (Ryki; Lublin, Poland) .................................................................................................................................................................................. 4853

Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy. M. TIMMER, J.-M. WERNER, G. RÖHN, M. ORTMANN, T. BLAU, C. CRAMER, P. STAVRINOU, B. KRISCHEK, P. MALLMAN, R. GOLDBRUNNER (Cologne, Germany) .................................................................................................................................................................. 4859

Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropism in Patients with Colorectal Cancer. R. DIVELLA, A. DANIELE, R. DE LUCA, M. SIMONE, E. NAGLIERI, E. SAVINO, I. ABBATE, C.D. GADALETÀ, G. RANIERI (Bari, Italy) .................................................................................................................................................................. 4867


Expression of Cancer Stem Cell-associated DKK1 mRNA Serves as Prognostic Marker for Hepatocellular Carcinoma. T. SAKABE, J. AZUMI, Y. UMEKITA, K. TORIGUCHI, E. HATANO, Y. HIROOKA, G. SHIOTA (Yonago; Kyoto, Japan) .......................................................................................................................................................... 4881


Contents continued on the preceding page